A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors

被引：0
|
作者：
Jordan D. Berlin
Dona B. Alberti
Rhoda Z. Arzoomanian
Chris A. Feierabend
Kris J. Simon
Kim A. Binger
Rebecca M. Marnocha
George Wilding
机构：
[1] University of Wisconsin,Division of Oncology
来源：
Investigational New Drugs | 1998年 / 16卷
关键词：
gemcitabine; 5-fluorouracil; leucovorin; phase I study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Introduction: This was a dose escalation phase I trial designed to establish the MTD (maximum tolerated dose) and toxicity profile of the combination of gemcitabine, leucovorin and 5-fluorouracil (5-FU).
引用
收藏
页码：325 / 330
页数：5
相关论文
共 50 条
  • [21] Phase I study of oxaliplatin in combination with 5-fluorouracil (5-FU), leucovorin (LV) and capecitabine (ORAL FOLFOX-6) in patients with advanced or metastatic solid tumors.
    Hegeman, RB
    Mulkerin, D
    Thomas, J
    Alberti, D
    Binger, K
    Marnocha, R
    Kolesar, J
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 149S - 149S
  • [22] A phase I study of 5-fluorouracil, leucovorin and levamisole
    J. F. Cleary
    Rhoda Arzoomanian
    Donna Alberti
    Chris Feierabend
    Barry Storer
    Pauline Witt
    P. P. Carbone
    George Wilding
    Cancer Chemotherapy and Pharmacology, 1997, 39 : 300 - 306
  • [23] A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies
    Petit, T
    Aylesworth, C
    Burris, H
    Ravdin, P
    Rodriguez, G
    Smith, L
    Peacock, N
    Smetzer, L
    Bellet, R
    Von Hoff, DD
    Rowinsky, EK
    ANNALS OF ONCOLOGY, 1999, 10 (02) : 223 - 229
  • [24] PHASE-II STUDY OF 5-FLUOROURACIL LEUCOVORIN FOR PEDIATRIC-PATIENTS WITH MALIGNANT SOLID TUMORS
    PRATT, CB
    MEYER, WH
    HOWLETT, N
    DOUGLASS, EC
    BOWMAN, LC
    POE, D
    MOUNCE, K
    KUN, LE
    HOUGHTON, JA
    CANCER, 1994, 74 (09) : 2593 - 2598
  • [25] Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, anti leucovorin in patients with advanced solid tumors
    Saltz, LB
    Kanowitz, J
    Kemeny, NE
    Schaaf, L
    Spriggs, D
    Staton, BA
    Berkery, R
    Steger, C
    Eng, M
    Dietz, A
    Locker, P
    Kelsen, DP
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (11) : 2959 - 2967
  • [26] A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
    Fakih, Marwan G.
    Fetterly, Gerald
    Egorin, Merrill J.
    Muindi, Josephia R.
    Espinoza-Delgado, Igor
    Zwiebel, James A.
    Litwin, Alan
    Holleran, Julianne L.
    Wang, Kangsheng
    Diasio, Robert B.
    CLINICAL CANCER RESEARCH, 2010, 16 (14) : 3786 - 3794
  • [27] A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-fluorouracil in patients with advanced solid tumors
    Souglakos, J
    Kakolyris, S
    Vardakis, N
    Androulakis, N
    Mavroudis, D
    Vamvakas, L
    Kouroussis, C
    Agelaki, S
    Saridaki, Z
    Georgoulias, V
    CANCER INVESTIGATION, 2005, 23 (06) : 505 - 510
  • [28] A phase I study of etirinotecan pegol in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Krishnamurthi, Smitha S.
    Chadha, Manpreet
    Rodal, Mary Beth
    Weiss, Glen J.
    Bokar, Joseph A.
    Jameson, Gayle S.
    Mast, Catherine Patricia
    Zhao, Carol
    Waluch, Bridget
    Hoch, Ute
    Hannah, Alison
    Dowlati, Afshin
    Meropol, Neal J.
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [29] Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors
    Bendell, JC
    Eder, JP
    Clark, JW
    Fidias, P
    Lynch, TJ
    Seiden, MV
    Ryan, DP
    CANCER, 2005, 103 (09) : 1925 - 1931
  • [30] Triplet therapy with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer
    Viúdez, A
    Rodríguez, J
    De la Cámara, J
    Salgado, E
    Chopitea, A
    Gil-Bazo, I
    García-Foncillas, J
    Valero, J
    Espinós, J
    Martin-Algarra, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 376S - 376S
12345